BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...series A round. The company hopes to start clinical trials next year of lead program CALY-002...
...as a target for autoimmune and inflammatory diseases, Calypso’s work in parallel on IL-15 antagonist CALY-002...
...In a 2017 paper , Vicari, Calypso co-founder and CSO Yolande Chvatchko and colleagues described CALY-002...
BioCentury | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...antibody CALY-002, which it aims to have in human trials for eosinophilic esophagitis in 2020. CALY-002...
...should last the company about two and a half years, at which point he thinks CALY-002...
...an undisclosed orphan disease. Calypso Biotech B.V., Amsterdam, the Netherlands Mark Zipkin Calypso Biotech S.A. Merck KGaA Interleukin-15 (IL-15) Eosinophilic esophagitis CALY-002...
BioCentury | Feb 21, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...antibody CALY-002, which it aims to have in human trials for eosinophilic esophagitis in 2020. CALY-002...
...should last the company about two and a half years, at which point he thinks CALY-002...
...to focus on eosinophilic esophagitis and an undisclosed orphan disease. Mark Zipkin Calypso Biotech S.A. Merck KGaA Interleukin-15 (IL-15) Eosinophilic esophagitis CALY-002...
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...targeting celiac disease. On May 14, it received exclusive, worldwide rights from iDD Biotech to CALY-002...
BioCentury | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

...iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002 , a humanized mAb, to treat refractory...
...refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties. CALY-002...
Items per page:
1 - 5 of 5